Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia

MLA

Waled Bahaj, et al. “Novel Scheme for Defining the Clinical Implications of TP53 Mutations in Myeloid Neoplasia.” Journal of Hematology & Oncology, vol. 16, no. 1, Aug. 2023, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s13045-023-01480-y.

APA

Waled Bahaj, Tariq Kewan, Carmelo Gurnari, Arda Durmaz, Ben Ponvilawan, Ishani Pandit, Yasuo Kubota, Olisaemeka D. Ogbue, Misam Zawit, Yazan Madanat, Taha Bat, Suresh K. Balasubramanian, Hussein Awada, Ramsha Ahmed, Minako Mori, Manja Meggendorfer, Torsten Haferlach, Valeria Visconte, & Jaroslaw P. Maciejewski. (2023). Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia. Journal of Hematology & Oncology, 16(1), 1–12. https://doi.org/10.1186/s13045-023-01480-y

Chicago

Waled Bahaj, Tariq Kewan, Carmelo Gurnari, Arda Durmaz, Ben Ponvilawan, Ishani Pandit, Yasuo Kubota, et al. 2023. “Novel Scheme for Defining the Clinical Implications of TP53 Mutations in Myeloid Neoplasia.” Journal of Hematology & Oncology 16 (1): 1–12. doi:10.1186/s13045-023-01480-y.